{"gene":"GLUD2","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2000,"finding":"Recombinant GLUD2-encoded hGDH2 is completely insensitive to GTP inhibition (IC50 >5,000 µM) unlike GLUD1-encoded hGDH1 (IC50 = 0.20 µM), and shows ~1,600% activation by 1.0 mM L-leucine versus ~75% for hGDH1. ADP synergizes with L-leucine to permit activation at physiologically relevant concentrations. These distinct allosteric mechanisms were established using purified recombinant enzymes expressed in Sf9 cells.","method":"Recombinant protein expression in Sf9 cells; enzyme kinetics; allosteric regulation assays with GTP, ADP, L-leucine","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic reconstitution with purified recombinant proteins, replicated across multiple allosteric effectors, foundational mechanism paper","pmids":["11032875"],"is_preprint":false},{"year":2003,"finding":"Site-directed mutagenesis of GLUD1 at positions corresponding to GLUD2 differences showed that Gly456Ala substitution confers GTP resistance (IC50 raised from 0.19 to 2.8 µM) and Arg443Ser substitution virtually abolishes basal activity while rendering the enzyme dependent on ADP for function. These two substitutions are the main evolutionary changes responsible for hGDH2's adaptation to nerve tissue.","method":"Site-directed mutagenesis of GLUD1; enzyme kinetic assays; recombinant protein expression","journal":"Neurochemistry international","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro mutagenesis with quantitative kinetic characterization, two orthogonal substitutions tested, clear mechanistic conclusion","pmids":["12742085"],"is_preprint":false},{"year":2007,"finding":"Purified recombinant wild-type hGDH2 is dissociated from GTP control, regulated almost entirely by ADP and/or L-leucine, and has activity fine-tuned to the relatively low cellular pH of synaptic astrocytes. A double hGDH1 mutant carrying both Arg443Ser and Gly456Ala did not fully recapitulate all properties of hGDH2, indicating that additional amino acid changes act in concert with these two substitutions.","method":"Recombinant protein expression and purification; enzyme kinetics; site-directed mutagenesis; pH-activity profiling","journal":"Journal of neuroscience research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis, replicated in two publications (PMIDs 17253646 and 17924438)","pmids":["17253646","17924438"],"is_preprint":false},{"year":2009,"finding":"GLUD2/EGFP fusion constructs transfected into COS7, HeLa, CHO, HEK293, and SHSY-5Y cells co-localize predominantly with mitochondrial marker DsRed2-Mito and to a lesser extent with ER marker DsRed2-ER. Deletion of the signal sequence prevents mitochondrial entry. Western blot identifies a ~90 kDa mitochondrial band and a ~95 kDa ER-associated band representing full-length unprocessed hGDH2.","method":"Confocal microscopy of EGFP fusions; co-transfection with organelle markers; Western blot fractionation; deletion mutagenesis","journal":"Biochemistry and cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct live-imaging localization with functional deletion analysis, replicated across five cell lines, fractionation data corroborating imaging","pmids":["19448744"],"is_preprint":false},{"year":2009,"finding":"A rare gain-of-function GLUD2 variant (T1492G; Ser445Ala) shows enhanced basal catalytic activity that is resistant to GTP inhibition but markedly sensitive to modulation by estrogens. This was established by biochemical analysis of the recombinant Ala445-hGDH2 variant.","method":"Recombinant protein expression; enzyme kinetics; allosteric modulation assays with GTP and estrogens","journal":"European journal of human genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinetic characterization of specific variant, replicated across three PD cohorts for the genetic finding, biochemical mechanism well-defined","pmids":["19826450"],"is_preprint":false},{"year":2009,"finding":"Site-directed mutations in the regulatory domain (antenna and pivot helix) of hGDH2 reveal distinct roles: antenna mutations (Gln441Arg, Ser445Leu) increase basal activity without altering allosteric properties; pivot helix mutations (Lys450Glu, His454Tyr) drastically reduce basal activity and impair regulation; Ser448Pro reduces basal activity but leaves allosteric regulation intact. Pivot helix mutants are extremely heat labile, while antenna mutants are relatively thermostable.","method":"Site-directed mutagenesis of hGDH2; enzyme kinetics; thermostability assays; recombinant protein expression","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro mutagenesis with multiple substitutions and orthogonal assays (kinetics + thermostability), single lab","pmids":["19393024"],"is_preprint":false},{"year":2010,"finding":"Endogenous hGDH2 protein localizes to mitochondria in human testicular Sertoli cells and cerebral cortical astrocytes, as shown using a specific anti-hGDH2 antibody developed against the Ser443-containing epitope (residues 436–447). Western blot confirmed mitochondrial fractionation. Neurons showed only faint hGDH2 immunoreactivity in this study.","method":"Immunocytochemistry; immunofluorescence; Western blot with isoform-specific antibody; subcellular fractionation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — isoform-specific antibody with multiple complementary methods (ICC, IF, Western, fractionation) in human tissue","pmids":["20194501"],"is_preprint":false},{"year":2011,"finding":"hGDH2 has dissociated its catalytic function from GTP control and can metabolize glutamate even when Krebs cycle-generated GTP levels are sufficient to inactivate hGDH1. Estrogens and neuroleptic drugs (haloperidol, perphenazine) inhibit hGDH2 more potently than hGDH1, and the evolutionary Arg443Ser substitution is largely responsible for this differential sensitivity.","method":"Recombinant enzyme assays; pharmacological inhibition studies; site-directed mutagenesis","journal":"Neurochemistry international","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinetic assays with recombinant proteins and mutagenesis identifying the structural basis; consistent with multiple prior studies","pmids":["21420458"],"is_preprint":false},{"year":2012,"finding":"Purified recombinant hGDH2 maintains a baseline activity of 3–8% of maximal capacity (versus 35–40% for hGDH1), conferred primarily by the Arg443Ser evolutionary change. This low basal activity is fully responsive to activation by rising ADP and/or L-leucine. The Arg443Ser change also makes hGDH2 markedly sensitive to inhibition by estrogens, spermidine, and EGCG at lower concentrations than hGDH1.","method":"Recombinant protein expression in Sf21 cells; enzyme kinetics; allosteric activation and inhibition assays","journal":"Neurochemistry international","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified recombinant proteins from independent expression system, orthogonal pharmacological characterization","pmids":["22658952"],"is_preprint":false},{"year":2012,"finding":"The first N-terminal amphipathic alpha-helix of the hGDH2 leader sequence is necessary and sufficient for mitochondrial import. Deletion of the entire leader sequence or of only this first alpha-helix prevented mitochondrial localization of GLUD2-EGFP constructs in HEK293, COS7, and SHSY-5Y cells, retaining the protein in the cytoplasm. Truncated leaders retaining only the second and/or third helices failed to restore import.","method":"Secondary structure prediction; GLUD2-EGFP deletion constructs; confocal microscopy with mitochondrial co-marker in three mammalian cell lines","journal":"Neurochemistry international","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic deletion mutagenesis with live imaging across three cell lines, multiple deletion constructs tested","pmids":["22709669"],"is_preprint":false},{"year":2012,"finding":"hGDH2 (and hGDH1) is expressed in testis mitochondrial fraction and in brain astrocytes as shown by Western blot using isoform-specific antibody. hGDH2 is also expressed in kidney proximal tubule epithelial cells. The two isoenzymes display distinct cellular distributions: Sertoli cells are strongly positive for hGDH2 but negative for hGDH1, while liver hepatocytes express very high hGDH1 but virtually no hGDH2.","method":"Isoform-specific antibodies; Western blot; immunohistochemistry; subcellular fractionation","journal":"Neurochemistry international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific antibody used in multiple human tissues, single lab, complements PMID 20194501","pmids":["22709674"],"is_preprint":false},{"year":2014,"finding":"Introduction of GLUD2 into murine glioma progenitor cells reverses the growth-inhibitory and metabolic flux defects caused by IDH1(R132H) mutation: GLUD2 expression rescues flux from glutamine and glucose to lipids and restores tumor growth. Orthotopic growth of IDH1-mutant glioma is inhibited by GLUD1/2 knockdown. Glutamate, a GLUD2 substrate, supports glioma progenitor cell growth irrespective of IDH1 status.","method":"Retroviral introduction of GLUD2 into murine glioma cells; metabolic flux analysis (13C tracing); orthotopic tumor implantation; shRNA knockdown; cell growth assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic gain-of-function and loss-of-function with metabolic flux readout and in vivo tumor assay, multiple orthogonal methods","pmids":["25225364"],"is_preprint":false},{"year":2015,"finding":"hGDH2 is expressed in steroid-producing cells of adrenal cortex, testis, ovaries, and placenta. Steroid hormones interact differentially with hGDH1 and hGDH2. The distinct expression of hGDH2 (but not hGDH1) in Sertoli cells and matching of hGDH2 expression with the cholesterol side chain cleavage system in adrenals was established using isoform-specific antibodies.","method":"Immunohistochemistry with isoform-specific antibodies; functional steroid hormone interaction assays","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — isoform-specific antibody IHC corroborated by functional pharmacological interaction assays, single lab","pmids":["26241911"],"is_preprint":false},{"year":2015,"finding":"hGDH2 immunoreactivity is detected in the cytoplasm of large cortical neurons within structures resembling mitochondria, distributed either in the perikaryon or in the cell periphery near synaptic terminals, in addition to astrocytes. Double immunofluorescence suggests that peripheral neuronal hGDH2 labels presynaptic mitochondria. This contrasts with hGDH1, which is restricted to glial cells.","method":"Immunohistochemistry; immunofluorescence with confocal microscopy; double labeling with glial and neuronal markers; isoform-specific antibodies on human cortical tissue","journal":"Molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by IF in human tissue with isoform-specific antibody and double labeling, single lab","pmids":["26399640"],"is_preprint":false},{"year":2016,"finding":"Transgenic mice carrying the human GLUD2 gene show metabolic effects centered on the tricarboxylic acid cycle during postnatal brain development, affecting genes involved in neuronal development. GLUD2 introduction did not affect glutamate levels but altered TCA cycle metabolites, suggesting GLUD2 affects carbon flux, possibly supporting lipid biosynthesis during early brain development.","method":"Transgenic mice (BAC insertion of human GLUD2); transcriptome analysis; metabolome analysis during postnatal brain development","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic model with transcriptome and metabolome readouts, but metabolic mechanism inferred rather than directly demonstrated","pmids":["27118840"],"is_preprint":false},{"year":2019,"finding":"Expression of hGDH2 in pancreatic β-cells of GLUD2 transgenic mice maintains 2.6-fold higher fasting serum insulin levels and lower fasting blood glucose compared to wild-type. L-leucine had little effect on already-high insulin in Tg mice, suggesting that under high ADP levels prevailing during fasting, hGDH2-mediated glutamate flux is near maximal. GLUD2 does not significantly affect glucose-stimulated insulin secretion.","method":"GLUD2 transgenic mice; fasting blood glucose measurement; serum insulin ELISA; L-leucine and glucose challenge tests; isoform-specific antibody confirmation of β-cell expression","journal":"Metabolism: clinical and experimental","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic model with multiple physiological readouts, mechanism linked to ADP-dependent hGDH2 activation, single lab","pmids":["31400387"],"is_preprint":false},{"year":2020,"finding":"AAV-expressed GLUD2 Ser445Ala gain-of-function mutant in the substantia nigra of MPTP-PD model mice exacerbates dopaminergic neuron death, movement deficits, reduces glutamate transporter expression/function, and damages mitochondrial function by decreasing succinate dehydrogenase activity to impede the TCA cycle. Downregulation of BDNF/Nrf2 signaling was also identified as a downstream consequence.","method":"AAV-mediated in vivo gene delivery; MPTP mouse model; behavioral testing; metabolomics (GC-Q-TOF/MS); succinate dehydrogenase activity assay; Western blot; glutamate transporter functional assay","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo gain-of-function with multiple orthogonal readouts (behavioral, metabolomic, enzymatic, molecular), mechanistically links GLUD2 variant to TCA cycle impairment","pmids":["33093440"],"is_preprint":false},{"year":2024,"finding":"In GLUD2 transgenic mice, theta-burst-evoked long-term potentiation (LTP) is markedly enhanced at hippocampal CA3-CA1 synapses, with patch-clamp recordings revealing increased spontaneous NMDA receptor currents in CA1 pyramidal neurons. D-lactate blocked LTP enhancement, implicating L-lactate-dependent glia-neuron interaction as the mechanism. Transgenic mice also exhibit increased dendritic spine density and improved complex cognitive functions.","method":"GLUD2 transgenic mice; field recordings of theta-burst LTP; whole-cell patch-clamp of CA1 neurons; D-lactate pharmacological block; dendritic spine counting; behavioral cognitive testing","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic electrophysiology with pharmacological dissection and behavioral readout, single lab, mechanism of lactate dependence needs further validation","pmids":["38791334"],"is_preprint":false}],"current_model":"GLUD2 encodes hGDH2, a mitochondrial glutamate dehydrogenase isoenzyme expressed in brain astrocytes, cortical neurons, testicular Sertoli cells, and steroidogenic tissues, which evolved via key amino acid substitutions (Arg443Ser and Gly456Ala) that dissociate it from GTP inhibition, set its basal activity to <10% of capacity, and allow full activation by rising ADP and L-leucine; this unique regulatory mechanism enables hGDH2 to metabolize glutamate under high-energy conditions when the housekeeping hGDH1 is inactivated, supporting neurotransmitter recycling, TCA cycle anaplerosis, synaptic plasticity, and basal insulin secretion, while gain-of-function variants in its regulatory domain accelerate dopaminergic neurodegeneration by impairing mitochondrial function through succinate dehydrogenase inhibition."},"narrative":{"mechanistic_narrative":"GLUD2 encodes hGDH2, a human-specific mitochondrial glutamate dehydrogenase isoenzyme whose defining feature is a regulatory rewiring that dissociates catalysis from the GTP inhibition that controls the housekeeping isoenzyme hGDH1, leaving hGDH2 governed almost entirely by activation through ADP and L-leucine [PMID:11032875, PMID:17253646, PMID:17924438]. Two evolutionary amino acid substitutions account for this adaptation: Gly456Ala confers GTP resistance, while Arg443Ser collapses basal activity to a few percent of maximal capacity and renders the enzyme dependent on ADP for function [PMID:12742085, PMID:22658952]; the same regulatory domain — comprising the antenna and pivot helix — tunes basal activity, allosteric responsiveness, and thermostability, and Arg443Ser additionally confers heightened sensitivity to inhibition by estrogens, neuroleptics, spermidine, and EGCG [PMID:19393024, PMID:21420458]. This regulatory design allows hGDH2 to oxidize glutamate under high-energy conditions that silence hGDH1, feeding carbon into the TCA cycle [PMID:11032875, PMID:27118840]. The protein is imported into mitochondria via an N-terminal amphipathic leader helix that is necessary and sufficient for import [PMID:19448744, PMID:22709669], and is expressed in brain astrocytes and cortical neurons, testicular Sertoli cells, kidney proximal tubule, and steroidogenic tissues, with a cellular distribution distinct from hGDH1 [PMID:20194501, PMID:22709674, PMID:26399640]. Functionally, hGDH2 supports synaptic plasticity through enhanced hippocampal LTP and dendritic spine density via lactate-dependent glia-neuron interaction [PMID:38791334], sustains ADP-driven basal insulin secretion during fasting [PMID:31400387], and rescues glutamine/glucose carbon flux to lipids and tumor growth in IDH1-mutant glioma [PMID:25225364]. A gain-of-function Ser445Ala variant elevates basal activity and, when overexpressed in nigral dopaminergic neurons, exacerbates neurodegeneration by impairing succinate dehydrogenase activity and TCA cycle flux [PMID:19826450, PMID:33093440].","teleology":[{"year":2000,"claim":"Established that the GLUD2 product hGDH2 is a regulatorily distinct isoenzyme rather than a redundant copy, by showing it is completely insensitive to GTP and hyperresponsive to L-leucine.","evidence":"Enzyme kinetics on purified recombinant hGDH2 vs hGDH1 expressed in Sf9 cells, testing GTP, ADP, and L-leucine","pmids":["11032875"],"confidence":"High","gaps":["Did not identify which residues confer the altered regulation","Tested in vitro only, not in cellular context"]},{"year":2003,"claim":"Pinpointed the molecular basis of hGDH2's adaptation by showing two substitutions (Gly456Ala for GTP resistance, Arg443Ser for ADP-dependence) recapitulate the key regulatory differences.","evidence":"Site-directed mutagenesis of GLUD1 to GLUD2-corresponding positions with kinetic characterization of recombinant proteins","pmids":["12742085"],"confidence":"High","gaps":["Did not test whether the two changes alone fully reconstitute hGDH2 behavior","No structural model of the altered regulatory site"]},{"year":2007,"claim":"Refined the regulatory model by showing the two key substitutions are necessary but insufficient, implicating additional cooperating residues and pH tuning to the synaptic astrocyte environment.","evidence":"Recombinant reconstitution, double-mutant analysis, and pH-activity profiling (two corroborating publications)","pmids":["17253646","17924438"],"confidence":"High","gaps":["Identity of the additional contributing residues not defined","Physiological pH environment inferred, not measured in situ"]},{"year":2009,"claim":"Defined the regulatory domain architecture (antenna vs pivot helix) and assigned distinct roles to its residues in setting basal activity, allosteric responsiveness, and thermostability.","evidence":"Panel of site-directed mutations in the hGDH2 regulatory domain with kinetic and thermostability assays","pmids":["19393024"],"confidence":"High","gaps":["Structural mechanism linking heat lability to allosteric impairment not resolved","Single lab"]},{"year":2009,"claim":"Connected GLUD2 regulatory variation to disease by characterizing a gain-of-function Ser445Ala variant with elevated GTP-resistant basal activity and estrogen sensitivity.","evidence":"Recombinant kinetic and allosteric characterization of the Ala445-hGDH2 variant, with genetic association across PD cohorts","pmids":["19826450"],"confidence":"High","gaps":["Causal mechanism in neurons not addressed at this stage","Effect size of genetic association limited"]},{"year":2009,"claim":"Determined how hGDH2 reaches its functional compartment, establishing mitochondrial localization with a minor ER pool and a signal-sequence-dependent import requirement.","evidence":"EGFP fusion confocal imaging with organelle markers, deletion mutagenesis, and Western fractionation across five cell lines","pmids":["19448744"],"confidence":"High","gaps":["Functional significance of the ER-associated unprocessed pool unknown","Overexpression of fusion construct may not reflect endogenous targeting"]},{"year":2010,"claim":"Confirmed endogenous mitochondrial localization of hGDH2 in specific human cell types using an isoform-specific antibody, validating the recombinant findings in native tissue.","evidence":"Isoform-specific anti-hGDH2 antibody ICC/IF/Western and fractionation in human testis and cortex","pmids":["20194501"],"confidence":"High","gaps":["Faint neuronal signal left neuronal expression unresolved","Did not address function in these cell types"]},{"year":2012,"claim":"Quantified hGDH2's low basal activity (3–8% of maximal) and attributed it primarily to Arg443Ser, while mapping its differential pharmacological inhibitor sensitivity.","evidence":"Recombinant kinetics in Sf21 cells with allosteric activation/inhibition assays","pmids":["22658952"],"confidence":"High","gaps":["Physiological relevance of inhibitor sensitivities in vivo not established"]},{"year":2012,"claim":"Localized the mitochondrial import signal to the first N-terminal amphipathic alpha-helix, shown necessary and sufficient for targeting.","evidence":"Systematic GLUD2-EGFP leader deletion constructs with confocal imaging in three cell lines","pmids":["22709669"],"confidence":"High","gaps":["Identity of the import receptor/machinery not defined","Based on fusion constructs"]},{"year":2012,"claim":"Expanded the tissue map showing hGDH2 occupies a distinct expression niche from hGDH1, including Sertoli cells and kidney proximal tubule.","evidence":"Isoform-specific antibody Western, IHC, and fractionation across human tissues","pmids":["22709674"],"confidence":"Medium","gaps":["Single lab","Functional consequence of tissue-specific distribution not tested"]},{"year":2014,"claim":"Demonstrated a metabolic role for GLUD2 in cancer by showing it rescues glutamine/glucose carbon flux to lipids and tumor growth in IDH1-mutant glioma.","evidence":"Retroviral GLUD2 introduction with 13C flux tracing, shRNA knockdown, and orthotopic tumor assays","pmids":["25225364"],"confidence":"High","gaps":["Used murine glioma model and combined GLUD1/2 knockdown","GLUD2-specific contribution vs GLUD1 not fully separated in vivo"]},{"year":2015,"claim":"Linked hGDH2 to steroidogenic and neuronal contexts, finding expression matched to the cholesterol side-chain cleavage system and in presynaptic neuronal mitochondria.","evidence":"Isoform-specific antibody IHC/IF with steroid hormone interaction assays and neuronal double-labeling in human tissue","pmids":["26241911","26399640"],"confidence":"Medium","gaps":["Functional role in steroidogenic and presynaptic compartments not directly tested","Single lab"]},{"year":2016,"claim":"Provided in vivo evidence that GLUD2 reshapes TCA cycle carbon flux during brain development without altering glutamate pools.","evidence":"GLUD2 BAC transgenic mice with transcriptome and metabolome profiling during postnatal development","pmids":["27118840"],"confidence":"Medium","gaps":["Lipid biosynthesis link inferred rather than measured","Mechanism connecting flux changes to developmental genes unresolved"]},{"year":2019,"claim":"Showed a physiological metabolic output of hGDH2 in vivo, sustaining elevated fasting insulin via ADP-driven glutamate flux.","evidence":"GLUD2 transgenic mice with fasting glucose/insulin measurement and leucine/glucose challenge","pmids":["31400387"],"confidence":"Medium","gaps":["Direct demonstration of beta-cell glutamate flux not performed","Single lab"]},{"year":2020,"claim":"Established the disease mechanism of the Ser445Ala gain-of-function variant, linking it to dopaminergic neurodegeneration through succinate dehydrogenase inhibition and TCA cycle impairment.","evidence":"AAV delivery of GLUD2 Ser445Ala into substantia nigra of MPTP mice with behavioral, metabolomic, enzymatic, and molecular readouts","pmids":["33093440"],"confidence":"High","gaps":["Causal chain from SDH inhibition to BDNF/Nrf2 downregulation not fully dissected","Overexpression model"]},{"year":2024,"claim":"Connected hGDH2 to synaptic plasticity by showing it enhances hippocampal LTP and dendritic spine density through lactate-dependent glia-neuron interaction.","evidence":"GLUD2 transgenic mouse LTP field recordings, CA1 patch-clamp, D-lactate block, spine counting, and cognitive testing","pmids":["38791334"],"confidence":"Medium","gaps":["Mechanism of lactate dependence needs further validation","Single lab"]},{"year":null,"claim":"The endogenous physiological substrate flux and in vivo regulatory state of hGDH2 across its tissue niches, and how its low basal activity is dynamically engaged, remain incompletely defined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of the rewired regulatory site reported in the corpus","Direct in situ measurement of ADP/leucine-driven hGDH2 activation lacking","Functional role in steroidogenic and renal tissues uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,2,8]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,7]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[3,6,9,13]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[11,14,16]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[17]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P49448","full_name":"Glutamate dehydrogenase 2, mitochondrial","aliases":[],"length_aa":558,"mass_kda":61.4,"function":"Important for recycling the chief excitatory neurotransmitter, glutamate, during neurotransmission","subcellular_location":"Mitochondrion matrix","url":"https://www.uniprot.org/uniprotkb/P49448/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GLUD2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GLUD2","total_profiled":1310},"omim":[{"mim_id":"312750","title":"RETT SYNDROME; RTT","url":"https://www.omim.org/entry/312750"},{"mim_id":"300354","title":"INTELLECTUAL DEVELOPMENTAL DISORDER, X-LINKED, SYNDROMIC, CABEZAS TYPE; MRXSC","url":"https://www.omim.org/entry/300354"},{"mim_id":"300144","title":"GLUTAMATE DEHYDROGENASE 2; GLUD2","url":"https://www.omim.org/entry/300144"},{"mim_id":"168600","title":"PARKINSON DISEASE, LATE-ONSET; PD","url":"https://www.omim.org/entry/168600"},{"mim_id":"138130","title":"GLUTAMATE DEHYDROGENASE 1; GLUD1","url":"https://www.omim.org/entry/138130"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":3.7},{"tissue":"testis","ntpm":14.8}],"url":"https://www.proteinatlas.org/search/GLUD2"},"hgnc":{"alias_symbol":[],"prev_symbol":["GLUDP1"]},"alphafold":{"accession":"P49448","domains":[{"cath_id":"3.40.50.10860","chopping":"112-264","consensus_level":"high","plddt":97.9022,"start":112,"end":264},{"cath_id":"3.40.50.720","chopping":"265-451_500-558","consensus_level":"medium","plddt":96.3628,"start":265,"end":558}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49448","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49448-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49448-F1-predicted_aligned_error_v6.png","plddt_mean":90.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GLUD2","jax_strain_url":"https://www.jax.org/strain/search?query=GLUD2"},"sequence":{"accession":"P49448","fasta_url":"https://rest.uniprot.org/uniprotkb/P49448.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49448/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49448"}},"corpus_meta":[{"pmid":"25225364","id":"PMC_25225364","title":"Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25225364","citation_count":90,"is_preprint":false},{"pmid":"11032875","id":"PMC_11032875","title":"Nerve tissue-specific (GLUD2) and housekeeping (GLUD1) human glutamate dehydrogenases are regulated by distinct allosteric mechanisms: implications for biologic function.","date":"2000","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11032875","citation_count":79,"is_preprint":false},{"pmid":"24357660","id":"PMC_24357660","title":"Type 1 metabotropic glutamate receptors (mGlu1) trigger the gating of GluD2 delta glutamate receptors.","date":"2013","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/24357660","citation_count":67,"is_preprint":false},{"pmid":"20194501","id":"PMC_20194501","title":"Human GLUD2 glutamate dehydrogenase is expressed in neural and testicular supporting cells.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20194501","citation_count":58,"is_preprint":false},{"pmid":"19420242","id":"PMC_19420242","title":"The N-terminal domain of GluD2 (GluRdelta2) recruits presynaptic terminals and regulates synaptogenesis in the cerebellum in vivo.","date":"2009","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19420242","citation_count":57,"is_preprint":false},{"pmid":"12742085","id":"PMC_12742085","title":"Study of structure-function relationships in human glutamate dehydrogenases reveals novel molecular mechanisms for the regulation of the nerve tissue-specific (GLUD2) isoenzyme.","date":"2003","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/12742085","citation_count":56,"is_preprint":false},{"pmid":"21420458","id":"PMC_21420458","title":"The human GLUD2 glutamate dehydrogenase and its regulation in health and disease.","date":"2011","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/21420458","citation_count":48,"is_preprint":false},{"pmid":"23141067","id":"PMC_23141067","title":"Presynaptically released Cbln1 induces dynamic axonal structural changes by interacting with GluD2 during cerebellar synapse formation.","date":"2012","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/23141067","citation_count":48,"is_preprint":false},{"pmid":"19448744","id":"PMC_19448744","title":"Human GLUD1 and GLUD2 glutamate dehydrogenase localize to mitochondria and endoplasmic reticulum.","date":"2009","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/19448744","citation_count":47,"is_preprint":false},{"pmid":"19826450","id":"PMC_19826450","title":"Gain-of-function variant in GLUD2 glutamate dehydrogenase modifies Parkinson's disease onset.","date":"2009","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/19826450","citation_count":44,"is_preprint":false},{"pmid":"31625608","id":"PMC_31625608","title":"Expression mapping, quantification, and complex formation of GluD1 and GluD2 glutamate receptors in adult mouse brain.","date":"2019","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31625608","citation_count":38,"is_preprint":false},{"pmid":"33352118","id":"PMC_33352118","title":"GluD2- and Cbln1-mediated competitive interactions shape the dendritic arbors of cerebellar Purkinje cells.","date":"2020","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/33352118","citation_count":38,"is_preprint":false},{"pmid":"24352816","id":"PMC_24352816","title":"The discovery of human of GLUD2 glutamate dehydrogenase and its implications for cell function in health and disease.","date":"2013","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/24352816","citation_count":37,"is_preprint":false},{"pmid":"22840919","id":"PMC_22840919","title":"Cerebellar LTD vs. motor learning-lessons learned from studying GluD2.","date":"2012","source":"Neural networks : the official journal of the International Neural Network Society","url":"https://pubmed.ncbi.nlm.nih.gov/22840919","citation_count":37,"is_preprint":false},{"pmid":"22709674","id":"PMC_22709674","title":"Expression of human GLUD2 glutamate dehydrogenase in human tissues: functional implications.","date":"2012","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/22709674","citation_count":33,"is_preprint":false},{"pmid":"27118840","id":"PMC_27118840","title":"Mice carrying a human GLUD2 gene recapitulate aspects of human transcriptome and metabolome development.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27118840","citation_count":31,"is_preprint":false},{"pmid":"19428807","id":"PMC_19428807","title":"The human GLUD2 glutamate dehydrogenase: localization and functional aspects.","date":"2009","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/19428807","citation_count":30,"is_preprint":false},{"pmid":"32512155","id":"PMC_32512155","title":"The architecture of GluD2 ionotropic delta glutamate receptor elucidated by cryo-EM.","date":"2020","source":"Journal of structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/32512155","citation_count":28,"is_preprint":false},{"pmid":"27276689","id":"PMC_27276689","title":"mGlu1 receptor canonical signaling pathway contributes to the opening of the orphan GluD2 receptor.","date":"2016","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27276689","citation_count":27,"is_preprint":false},{"pmid":"27122040","id":"PMC_27122040","title":"GluD2 Endows Parallel Fiber-Purkinje Cell Synapses with a High Regenerative Capacity.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27122040","citation_count":27,"is_preprint":false},{"pmid":"22658952","id":"PMC_22658952","title":"The complex regulation of human glud1 and glud2 glutamate dehydrogenases and its implications in nerve tissue biology.","date":"2012","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/22658952","citation_count":27,"is_preprint":false},{"pmid":"30314897","id":"PMC_30314897","title":"Mitochondrial enzyme GLUD2 plays a critical role in glioblastoma progression.","date":"2018","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/30314897","citation_count":25,"is_preprint":false},{"pmid":"26661043","id":"PMC_26661043","title":"Pharmacology and Structural Analysis of Ligand Binding to the Orthosteric Site of Glutamate-Like GluD2 Receptors.","date":"2015","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26661043","citation_count":25,"is_preprint":false},{"pmid":"29207948","id":"PMC_29207948","title":"Homozygous GRID2 missense mutation predicts a shift in the D-serine binding domain of GluD2 in a case with generalized brain atrophy and unusual clinical features.","date":"2017","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29207948","citation_count":24,"is_preprint":false},{"pmid":"17253646","id":"PMC_17253646","title":"Properties and molecular evolution of human GLUD2 (neural and testicular tissue-specific) glutamate dehydrogenase.","date":"2007","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/17253646","citation_count":22,"is_preprint":false},{"pmid":"26241911","id":"PMC_26241911","title":"Expression of human GLUD1 and GLUD2 glutamate dehydrogenases in steroid producing tissues.","date":"2015","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26241911","citation_count":21,"is_preprint":false},{"pmid":"33112237","id":"PMC_33112237","title":"Probing the ionotropic activity of glutamate GluD2 receptor in HEK cells with genetically-engineered photopharmacology.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/33112237","citation_count":21,"is_preprint":false},{"pmid":"17924438","id":"PMC_17924438","title":"Properties and molecular evolution of human GLUD2 (neural and testicular tissue-specific) glutamate dehydrogenase.","date":"2007","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/17924438","citation_count":21,"is_preprint":false},{"pmid":"33093440","id":"PMC_33093440","title":"Functional validation of a human GLUD2 variant in a murine model of Parkinson's disease.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33093440","citation_count":19,"is_preprint":false},{"pmid":"27422263","id":"PMC_27422263","title":"Widening Spectrum of Cellular and Subcellular Expression of Human GLUD1 and GLUD2 Glutamate Dehydrogenases Suggests Novel Functions.","date":"2016","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/27422263","citation_count":19,"is_preprint":false},{"pmid":"23970854","id":"PMC_23970854","title":"Disruption of cerebellar microzonal organization in GluD2 (GluRδ2) knockout mouse.","date":"2013","source":"Frontiers in neural circuits","url":"https://pubmed.ncbi.nlm.nih.gov/23970854","citation_count":19,"is_preprint":false},{"pmid":"28877468","id":"PMC_28877468","title":"Cbln1 and Cbln4 Are Structurally Similar but Differ in GluD2 Binding Interactions.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28877468","citation_count":18,"is_preprint":false},{"pmid":"34454056","id":"PMC_34454056","title":"Role of Glutamine-Glutamate/GABA cycle and potential target GLUD2 in alleviation of rheumatoid arthritis by Tripterygium hypoglaucum (levl.) Hutch based on metabolomics and molecular pharmacology.","date":"2021","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34454056","citation_count":17,"is_preprint":false},{"pmid":"9674910","id":"PMC_9674910","title":"Evaluation of two X chromosomal candidate genes for Rett syndrome: glutamate dehydrogenase-2 (GLUD2) and rab GDP-dissociation inhibitor (GDI1).","date":"1998","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9674910","citation_count":17,"is_preprint":false},{"pmid":"26399640","id":"PMC_26399640","title":"Evolution of GLUD2 Glutamate Dehydrogenase Allows Expression in Human Cortical Neurons.","date":"2015","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/26399640","citation_count":16,"is_preprint":false},{"pmid":"32735769","id":"PMC_32735769","title":"D-Serine Potently Drives Ligand-Binding Domain Closure in the Ionotropic Glutamate Receptor GluD2.","date":"2020","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/32735769","citation_count":16,"is_preprint":false},{"pmid":"28387240","id":"PMC_28387240","title":"The low binding affinity of D-serine at the ionotropic glutamate receptor GluD2 can be attributed to the hinge region.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28387240","citation_count":16,"is_preprint":false},{"pmid":"36128700","id":"PMC_36128700","title":"Differences between the GluD1 and GluD2 receptors revealed by GluD1 X-ray crystallography, binding studies and molecular dynamics.","date":"2022","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/36128700","citation_count":14,"is_preprint":false},{"pmid":"22709669","id":"PMC_22709669","title":"Alpha helical structures in the leader sequence of human GLUD2 glutamate dehydrogenase responsible for mitochondrial import.","date":"2012","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/22709669","citation_count":12,"is_preprint":false},{"pmid":"19393024","id":"PMC_19393024","title":"Mutations in human GLUD2 glutamate dehydrogenase affecting basal activity and regulation.","date":"2009","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19393024","citation_count":11,"is_preprint":false},{"pmid":"23564161","id":"PMC_23564161","title":"Contribution of postsynaptic GluD2 to presynaptic R-type Ca(2+) channel function, glutamate release and long-term potentiation at parallel fiber to Purkinje cell synapses.","date":"2013","source":"Cerebellum (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23564161","citation_count":11,"is_preprint":false},{"pmid":"29777493","id":"PMC_29777493","title":"Transgenic Mice Carrying GLUD2 as a Tool for Studying the Expressional and the Functional Adaptation of this Positive Selected Gene in Human Brain Evolution.","date":"2018","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/29777493","citation_count":9,"is_preprint":false},{"pmid":"20599760","id":"PMC_20599760","title":"Flap loop of GluD2 binds to Cbln1 and induces presynaptic differentiation.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20599760","citation_count":7,"is_preprint":false},{"pmid":"22113500","id":"PMC_22113500","title":"The ins and outs of GluD2--why and how Purkinje cells use the special glutamate receptor.","date":"2012","source":"Cerebellum (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22113500","citation_count":6,"is_preprint":false},{"pmid":"33443132","id":"PMC_33443132","title":"Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome.","date":"2020","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33443132","citation_count":6,"is_preprint":false},{"pmid":"38791334","id":"PMC_38791334","title":"Evolution of Glutamate Metabolism via GLUD2 Enhances Lactate-Dependent Synaptic Plasticity and Complex Cognition.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38791334","citation_count":6,"is_preprint":false},{"pmid":"27033232","id":"PMC_27033232","title":"Developmental Hypothyroxinemia and Hypothyroidism Reduce Parallel Fiber-Purkinje Cell Synapses in Rat Offspring by Downregulation of Neurexin1/Cbln1/GluD2 Tripartite Complex.","date":"2016","source":"Biological trace element research","url":"https://pubmed.ncbi.nlm.nih.gov/27033232","citation_count":4,"is_preprint":false},{"pmid":"31400387","id":"PMC_31400387","title":"Transgenic expression of the positive selected human GLUD2 gene improves in vivo glucose homeostasis by regulating basic insulin secretion.","date":"2019","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/31400387","citation_count":3,"is_preprint":false},{"pmid":"15192816","id":"PMC_15192816","title":"[Fine mapping of Smith-Fineman-Myers syndrome and exclusion of GPC3, GPCR2 MST4 and GLUD2 as candidate genes].","date":"2004","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15192816","citation_count":2,"is_preprint":false},{"pmid":"27820843","id":"PMC_27820843","title":"Involvement of GluD2 in Fear-Conditioned Bradycardia in Mice.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27820843","citation_count":1,"is_preprint":false},{"pmid":"1855394","id":"PMC_1855394","title":"Confirmation, via in situ hybridization, of the occurrence of Robertsonian translocations during lemur evolution by localization of GLUDP1 DNA sequences on lemur chromosomes.","date":"1991","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1855394","citation_count":1,"is_preprint":false},{"pmid":"37345272","id":"PMC_37345272","title":"Structural insights into the ligand binding domain of GluD1 and GluD2 receptors.","date":"2023","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/37345272","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.15.649028","title":"Glutamate delta-1 receptors regulate a novel tonic excitatory conductance in the mouse bed nucleus of the stria terminalis and influence neuronal function","date":"2025-04-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.15.649028","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":29466,"output_tokens":4976,"usd":0.081519,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13250,"output_tokens":4605,"usd":0.090688,"stage2_stop_reason":"end_turn"},"total_usd":0.172207,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"Recombinant GLUD2-encoded hGDH2 is completely insensitive to GTP inhibition (IC50 >5,000 µM) unlike GLUD1-encoded hGDH1 (IC50 = 0.20 µM), and shows ~1,600% activation by 1.0 mM L-leucine versus ~75% for hGDH1. ADP synergizes with L-leucine to permit activation at physiologically relevant concentrations. These distinct allosteric mechanisms were established using purified recombinant enzymes expressed in Sf9 cells.\",\n      \"method\": \"Recombinant protein expression in Sf9 cells; enzyme kinetics; allosteric regulation assays with GTP, ADP, L-leucine\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic reconstitution with purified recombinant proteins, replicated across multiple allosteric effectors, foundational mechanism paper\",\n      \"pmids\": [\"11032875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Site-directed mutagenesis of GLUD1 at positions corresponding to GLUD2 differences showed that Gly456Ala substitution confers GTP resistance (IC50 raised from 0.19 to 2.8 µM) and Arg443Ser substitution virtually abolishes basal activity while rendering the enzyme dependent on ADP for function. These two substitutions are the main evolutionary changes responsible for hGDH2's adaptation to nerve tissue.\",\n      \"method\": \"Site-directed mutagenesis of GLUD1; enzyme kinetic assays; recombinant protein expression\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro mutagenesis with quantitative kinetic characterization, two orthogonal substitutions tested, clear mechanistic conclusion\",\n      \"pmids\": [\"12742085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Purified recombinant wild-type hGDH2 is dissociated from GTP control, regulated almost entirely by ADP and/or L-leucine, and has activity fine-tuned to the relatively low cellular pH of synaptic astrocytes. A double hGDH1 mutant carrying both Arg443Ser and Gly456Ala did not fully recapitulate all properties of hGDH2, indicating that additional amino acid changes act in concert with these two substitutions.\",\n      \"method\": \"Recombinant protein expression and purification; enzyme kinetics; site-directed mutagenesis; pH-activity profiling\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis, replicated in two publications (PMIDs 17253646 and 17924438)\",\n      \"pmids\": [\"17253646\", \"17924438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GLUD2/EGFP fusion constructs transfected into COS7, HeLa, CHO, HEK293, and SHSY-5Y cells co-localize predominantly with mitochondrial marker DsRed2-Mito and to a lesser extent with ER marker DsRed2-ER. Deletion of the signal sequence prevents mitochondrial entry. Western blot identifies a ~90 kDa mitochondrial band and a ~95 kDa ER-associated band representing full-length unprocessed hGDH2.\",\n      \"method\": \"Confocal microscopy of EGFP fusions; co-transfection with organelle markers; Western blot fractionation; deletion mutagenesis\",\n      \"journal\": \"Biochemistry and cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct live-imaging localization with functional deletion analysis, replicated across five cell lines, fractionation data corroborating imaging\",\n      \"pmids\": [\"19448744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A rare gain-of-function GLUD2 variant (T1492G; Ser445Ala) shows enhanced basal catalytic activity that is resistant to GTP inhibition but markedly sensitive to modulation by estrogens. This was established by biochemical analysis of the recombinant Ala445-hGDH2 variant.\",\n      \"method\": \"Recombinant protein expression; enzyme kinetics; allosteric modulation assays with GTP and estrogens\",\n      \"journal\": \"European journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinetic characterization of specific variant, replicated across three PD cohorts for the genetic finding, biochemical mechanism well-defined\",\n      \"pmids\": [\"19826450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Site-directed mutations in the regulatory domain (antenna and pivot helix) of hGDH2 reveal distinct roles: antenna mutations (Gln441Arg, Ser445Leu) increase basal activity without altering allosteric properties; pivot helix mutations (Lys450Glu, His454Tyr) drastically reduce basal activity and impair regulation; Ser448Pro reduces basal activity but leaves allosteric regulation intact. Pivot helix mutants are extremely heat labile, while antenna mutants are relatively thermostable.\",\n      \"method\": \"Site-directed mutagenesis of hGDH2; enzyme kinetics; thermostability assays; recombinant protein expression\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro mutagenesis with multiple substitutions and orthogonal assays (kinetics + thermostability), single lab\",\n      \"pmids\": [\"19393024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Endogenous hGDH2 protein localizes to mitochondria in human testicular Sertoli cells and cerebral cortical astrocytes, as shown using a specific anti-hGDH2 antibody developed against the Ser443-containing epitope (residues 436–447). Western blot confirmed mitochondrial fractionation. Neurons showed only faint hGDH2 immunoreactivity in this study.\",\n      \"method\": \"Immunocytochemistry; immunofluorescence; Western blot with isoform-specific antibody; subcellular fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isoform-specific antibody with multiple complementary methods (ICC, IF, Western, fractionation) in human tissue\",\n      \"pmids\": [\"20194501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"hGDH2 has dissociated its catalytic function from GTP control and can metabolize glutamate even when Krebs cycle-generated GTP levels are sufficient to inactivate hGDH1. Estrogens and neuroleptic drugs (haloperidol, perphenazine) inhibit hGDH2 more potently than hGDH1, and the evolutionary Arg443Ser substitution is largely responsible for this differential sensitivity.\",\n      \"method\": \"Recombinant enzyme assays; pharmacological inhibition studies; site-directed mutagenesis\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinetic assays with recombinant proteins and mutagenesis identifying the structural basis; consistent with multiple prior studies\",\n      \"pmids\": [\"21420458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Purified recombinant hGDH2 maintains a baseline activity of 3–8% of maximal capacity (versus 35–40% for hGDH1), conferred primarily by the Arg443Ser evolutionary change. This low basal activity is fully responsive to activation by rising ADP and/or L-leucine. The Arg443Ser change also makes hGDH2 markedly sensitive to inhibition by estrogens, spermidine, and EGCG at lower concentrations than hGDH1.\",\n      \"method\": \"Recombinant protein expression in Sf21 cells; enzyme kinetics; allosteric activation and inhibition assays\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified recombinant proteins from independent expression system, orthogonal pharmacological characterization\",\n      \"pmids\": [\"22658952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The first N-terminal amphipathic alpha-helix of the hGDH2 leader sequence is necessary and sufficient for mitochondrial import. Deletion of the entire leader sequence or of only this first alpha-helix prevented mitochondrial localization of GLUD2-EGFP constructs in HEK293, COS7, and SHSY-5Y cells, retaining the protein in the cytoplasm. Truncated leaders retaining only the second and/or third helices failed to restore import.\",\n      \"method\": \"Secondary structure prediction; GLUD2-EGFP deletion constructs; confocal microscopy with mitochondrial co-marker in three mammalian cell lines\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic deletion mutagenesis with live imaging across three cell lines, multiple deletion constructs tested\",\n      \"pmids\": [\"22709669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"hGDH2 (and hGDH1) is expressed in testis mitochondrial fraction and in brain astrocytes as shown by Western blot using isoform-specific antibody. hGDH2 is also expressed in kidney proximal tubule epithelial cells. The two isoenzymes display distinct cellular distributions: Sertoli cells are strongly positive for hGDH2 but negative for hGDH1, while liver hepatocytes express very high hGDH1 but virtually no hGDH2.\",\n      \"method\": \"Isoform-specific antibodies; Western blot; immunohistochemistry; subcellular fractionation\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific antibody used in multiple human tissues, single lab, complements PMID 20194501\",\n      \"pmids\": [\"22709674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Introduction of GLUD2 into murine glioma progenitor cells reverses the growth-inhibitory and metabolic flux defects caused by IDH1(R132H) mutation: GLUD2 expression rescues flux from glutamine and glucose to lipids and restores tumor growth. Orthotopic growth of IDH1-mutant glioma is inhibited by GLUD1/2 knockdown. Glutamate, a GLUD2 substrate, supports glioma progenitor cell growth irrespective of IDH1 status.\",\n      \"method\": \"Retroviral introduction of GLUD2 into murine glioma cells; metabolic flux analysis (13C tracing); orthotopic tumor implantation; shRNA knockdown; cell growth assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic gain-of-function and loss-of-function with metabolic flux readout and in vivo tumor assay, multiple orthogonal methods\",\n      \"pmids\": [\"25225364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"hGDH2 is expressed in steroid-producing cells of adrenal cortex, testis, ovaries, and placenta. Steroid hormones interact differentially with hGDH1 and hGDH2. The distinct expression of hGDH2 (but not hGDH1) in Sertoli cells and matching of hGDH2 expression with the cholesterol side chain cleavage system in adrenals was established using isoform-specific antibodies.\",\n      \"method\": \"Immunohistochemistry with isoform-specific antibodies; functional steroid hormone interaction assays\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — isoform-specific antibody IHC corroborated by functional pharmacological interaction assays, single lab\",\n      \"pmids\": [\"26241911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"hGDH2 immunoreactivity is detected in the cytoplasm of large cortical neurons within structures resembling mitochondria, distributed either in the perikaryon or in the cell periphery near synaptic terminals, in addition to astrocytes. Double immunofluorescence suggests that peripheral neuronal hGDH2 labels presynaptic mitochondria. This contrasts with hGDH1, which is restricted to glial cells.\",\n      \"method\": \"Immunohistochemistry; immunofluorescence with confocal microscopy; double labeling with glial and neuronal markers; isoform-specific antibodies on human cortical tissue\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by IF in human tissue with isoform-specific antibody and double labeling, single lab\",\n      \"pmids\": [\"26399640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Transgenic mice carrying the human GLUD2 gene show metabolic effects centered on the tricarboxylic acid cycle during postnatal brain development, affecting genes involved in neuronal development. GLUD2 introduction did not affect glutamate levels but altered TCA cycle metabolites, suggesting GLUD2 affects carbon flux, possibly supporting lipid biosynthesis during early brain development.\",\n      \"method\": \"Transgenic mice (BAC insertion of human GLUD2); transcriptome analysis; metabolome analysis during postnatal brain development\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic model with transcriptome and metabolome readouts, but metabolic mechanism inferred rather than directly demonstrated\",\n      \"pmids\": [\"27118840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Expression of hGDH2 in pancreatic β-cells of GLUD2 transgenic mice maintains 2.6-fold higher fasting serum insulin levels and lower fasting blood glucose compared to wild-type. L-leucine had little effect on already-high insulin in Tg mice, suggesting that under high ADP levels prevailing during fasting, hGDH2-mediated glutamate flux is near maximal. GLUD2 does not significantly affect glucose-stimulated insulin secretion.\",\n      \"method\": \"GLUD2 transgenic mice; fasting blood glucose measurement; serum insulin ELISA; L-leucine and glucose challenge tests; isoform-specific antibody confirmation of β-cell expression\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic model with multiple physiological readouts, mechanism linked to ADP-dependent hGDH2 activation, single lab\",\n      \"pmids\": [\"31400387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"AAV-expressed GLUD2 Ser445Ala gain-of-function mutant in the substantia nigra of MPTP-PD model mice exacerbates dopaminergic neuron death, movement deficits, reduces glutamate transporter expression/function, and damages mitochondrial function by decreasing succinate dehydrogenase activity to impede the TCA cycle. Downregulation of BDNF/Nrf2 signaling was also identified as a downstream consequence.\",\n      \"method\": \"AAV-mediated in vivo gene delivery; MPTP mouse model; behavioral testing; metabolomics (GC-Q-TOF/MS); succinate dehydrogenase activity assay; Western blot; glutamate transporter functional assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo gain-of-function with multiple orthogonal readouts (behavioral, metabolomic, enzymatic, molecular), mechanistically links GLUD2 variant to TCA cycle impairment\",\n      \"pmids\": [\"33093440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In GLUD2 transgenic mice, theta-burst-evoked long-term potentiation (LTP) is markedly enhanced at hippocampal CA3-CA1 synapses, with patch-clamp recordings revealing increased spontaneous NMDA receptor currents in CA1 pyramidal neurons. D-lactate blocked LTP enhancement, implicating L-lactate-dependent glia-neuron interaction as the mechanism. Transgenic mice also exhibit increased dendritic spine density and improved complex cognitive functions.\",\n      \"method\": \"GLUD2 transgenic mice; field recordings of theta-burst LTP; whole-cell patch-clamp of CA1 neurons; D-lactate pharmacological block; dendritic spine counting; behavioral cognitive testing\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic electrophysiology with pharmacological dissection and behavioral readout, single lab, mechanism of lactate dependence needs further validation\",\n      \"pmids\": [\"38791334\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GLUD2 encodes hGDH2, a mitochondrial glutamate dehydrogenase isoenzyme expressed in brain astrocytes, cortical neurons, testicular Sertoli cells, and steroidogenic tissues, which evolved via key amino acid substitutions (Arg443Ser and Gly456Ala) that dissociate it from GTP inhibition, set its basal activity to <10% of capacity, and allow full activation by rising ADP and L-leucine; this unique regulatory mechanism enables hGDH2 to metabolize glutamate under high-energy conditions when the housekeeping hGDH1 is inactivated, supporting neurotransmitter recycling, TCA cycle anaplerosis, synaptic plasticity, and basal insulin secretion, while gain-of-function variants in its regulatory domain accelerate dopaminergic neurodegeneration by impairing mitochondrial function through succinate dehydrogenase inhibition.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GLUD2 encodes hGDH2, a human-specific mitochondrial glutamate dehydrogenase isoenzyme whose defining feature is a regulatory rewiring that dissociates catalysis from the GTP inhibition that controls the housekeeping isoenzyme hGDH1, leaving hGDH2 governed almost entirely by activation through ADP and L-leucine [#0, #2]. Two evolutionary amino acid substitutions account for this adaptation: Gly456Ala confers GTP resistance, while Arg443Ser collapses basal activity to a few percent of maximal capacity and renders the enzyme dependent on ADP for function [#1, #8]; the same regulatory domain — comprising the antenna and pivot helix — tunes basal activity, allosteric responsiveness, and thermostability, and Arg443Ser additionally confers heightened sensitivity to inhibition by estrogens, neuroleptics, spermidine, and EGCG [#5, #7]. This regulatory design allows hGDH2 to oxidize glutamate under high-energy conditions that silence hGDH1, feeding carbon into the TCA cycle [#0, #14]. The protein is imported into mitochondria via an N-terminal amphipathic leader helix that is necessary and sufficient for import [#3, #9], and is expressed in brain astrocytes and cortical neurons, testicular Sertoli cells, kidney proximal tubule, and steroidogenic tissues, with a cellular distribution distinct from hGDH1 [#6, #10, #13]. Functionally, hGDH2 supports synaptic plasticity through enhanced hippocampal LTP and dendritic spine density via lactate-dependent glia-neuron interaction [#17], sustains ADP-driven basal insulin secretion during fasting [#15], and rescues glutamine/glucose carbon flux to lipids and tumor growth in IDH1-mutant glioma [#11]. A gain-of-function Ser445Ala variant elevates basal activity and, when overexpressed in nigral dopaminergic neurons, exacerbates neurodegeneration by impairing succinate dehydrogenase activity and TCA cycle flux [#4, #16].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that the GLUD2 product hGDH2 is a regulatorily distinct isoenzyme rather than a redundant copy, by showing it is completely insensitive to GTP and hyperresponsive to L-leucine.\",\n      \"evidence\": \"Enzyme kinetics on purified recombinant hGDH2 vs hGDH1 expressed in Sf9 cells, testing GTP, ADP, and L-leucine\",\n      \"pmids\": [\"11032875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify which residues confer the altered regulation\", \"Tested in vitro only, not in cellular context\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Pinpointed the molecular basis of hGDH2's adaptation by showing two substitutions (Gly456Ala for GTP resistance, Arg443Ser for ADP-dependence) recapitulate the key regulatory differences.\",\n      \"evidence\": \"Site-directed mutagenesis of GLUD1 to GLUD2-corresponding positions with kinetic characterization of recombinant proteins\",\n      \"pmids\": [\"12742085\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test whether the two changes alone fully reconstitute hGDH2 behavior\", \"No structural model of the altered regulatory site\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Refined the regulatory model by showing the two key substitutions are necessary but insufficient, implicating additional cooperating residues and pH tuning to the synaptic astrocyte environment.\",\n      \"evidence\": \"Recombinant reconstitution, double-mutant analysis, and pH-activity profiling (two corroborating publications)\",\n      \"pmids\": [\"17253646\", \"17924438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the additional contributing residues not defined\", \"Physiological pH environment inferred, not measured in situ\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the regulatory domain architecture (antenna vs pivot helix) and assigned distinct roles to its residues in setting basal activity, allosteric responsiveness, and thermostability.\",\n      \"evidence\": \"Panel of site-directed mutations in the hGDH2 regulatory domain with kinetic and thermostability assays\",\n      \"pmids\": [\"19393024\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism linking heat lability to allosteric impairment not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Connected GLUD2 regulatory variation to disease by characterizing a gain-of-function Ser445Ala variant with elevated GTP-resistant basal activity and estrogen sensitivity.\",\n      \"evidence\": \"Recombinant kinetic and allosteric characterization of the Ala445-hGDH2 variant, with genetic association across PD cohorts\",\n      \"pmids\": [\"19826450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal mechanism in neurons not addressed at this stage\", \"Effect size of genetic association limited\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Determined how hGDH2 reaches its functional compartment, establishing mitochondrial localization with a minor ER pool and a signal-sequence-dependent import requirement.\",\n      \"evidence\": \"EGFP fusion confocal imaging with organelle markers, deletion mutagenesis, and Western fractionation across five cell lines\",\n      \"pmids\": [\"19448744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional significance of the ER-associated unprocessed pool unknown\", \"Overexpression of fusion construct may not reflect endogenous targeting\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Confirmed endogenous mitochondrial localization of hGDH2 in specific human cell types using an isoform-specific antibody, validating the recombinant findings in native tissue.\",\n      \"evidence\": \"Isoform-specific anti-hGDH2 antibody ICC/IF/Western and fractionation in human testis and cortex\",\n      \"pmids\": [\"20194501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Faint neuronal signal left neuronal expression unresolved\", \"Did not address function in these cell types\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Quantified hGDH2's low basal activity (3–8% of maximal) and attributed it primarily to Arg443Ser, while mapping its differential pharmacological inhibitor sensitivity.\",\n      \"evidence\": \"Recombinant kinetics in Sf21 cells with allosteric activation/inhibition assays\",\n      \"pmids\": [\"22658952\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of inhibitor sensitivities in vivo not established\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Localized the mitochondrial import signal to the first N-terminal amphipathic alpha-helix, shown necessary and sufficient for targeting.\",\n      \"evidence\": \"Systematic GLUD2-EGFP leader deletion constructs with confocal imaging in three cell lines\",\n      \"pmids\": [\"22709669\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the import receptor/machinery not defined\", \"Based on fusion constructs\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Expanded the tissue map showing hGDH2 occupies a distinct expression niche from hGDH1, including Sertoli cells and kidney proximal tubule.\",\n      \"evidence\": \"Isoform-specific antibody Western, IHC, and fractionation across human tissues\",\n      \"pmids\": [\"22709674\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Functional consequence of tissue-specific distribution not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated a metabolic role for GLUD2 in cancer by showing it rescues glutamine/glucose carbon flux to lipids and tumor growth in IDH1-mutant glioma.\",\n      \"evidence\": \"Retroviral GLUD2 introduction with 13C flux tracing, shRNA knockdown, and orthotopic tumor assays\",\n      \"pmids\": [\"25225364\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Used murine glioma model and combined GLUD1/2 knockdown\", \"GLUD2-specific contribution vs GLUD1 not fully separated in vivo\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked hGDH2 to steroidogenic and neuronal contexts, finding expression matched to the cholesterol side-chain cleavage system and in presynaptic neuronal mitochondria.\",\n      \"evidence\": \"Isoform-specific antibody IHC/IF with steroid hormone interaction assays and neuronal double-labeling in human tissue\",\n      \"pmids\": [\"26241911\", \"26399640\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role in steroidogenic and presynaptic compartments not directly tested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided in vivo evidence that GLUD2 reshapes TCA cycle carbon flux during brain development without altering glutamate pools.\",\n      \"evidence\": \"GLUD2 BAC transgenic mice with transcriptome and metabolome profiling during postnatal development\",\n      \"pmids\": [\"27118840\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Lipid biosynthesis link inferred rather than measured\", \"Mechanism connecting flux changes to developmental genes unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed a physiological metabolic output of hGDH2 in vivo, sustaining elevated fasting insulin via ADP-driven glutamate flux.\",\n      \"evidence\": \"GLUD2 transgenic mice with fasting glucose/insulin measurement and leucine/glucose challenge\",\n      \"pmids\": [\"31400387\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct demonstration of beta-cell glutamate flux not performed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established the disease mechanism of the Ser445Ala gain-of-function variant, linking it to dopaminergic neurodegeneration through succinate dehydrogenase inhibition and TCA cycle impairment.\",\n      \"evidence\": \"AAV delivery of GLUD2 Ser445Ala into substantia nigra of MPTP mice with behavioral, metabolomic, enzymatic, and molecular readouts\",\n      \"pmids\": [\"33093440\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal chain from SDH inhibition to BDNF/Nrf2 downregulation not fully dissected\", \"Overexpression model\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected hGDH2 to synaptic plasticity by showing it enhances hippocampal LTP and dendritic spine density through lactate-dependent glia-neuron interaction.\",\n      \"evidence\": \"GLUD2 transgenic mouse LTP field recordings, CA1 patch-clamp, D-lactate block, spine counting, and cognitive testing\",\n      \"pmids\": [\"38791334\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of lactate dependence needs further validation\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The endogenous physiological substrate flux and in vivo regulatory state of hGDH2 across its tissue niches, and how its low basal activity is dynamically engaged, remain incompletely defined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of the rewired regulatory site reported in the corpus\", \"Direct in situ measurement of ADP/leucine-driven hGDH2 activation lacking\", \"Functional role in steroidogenic and renal tissues uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 2, 8]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [3, 6, 9, 13]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [11, 14, 16]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}